NASDAQ$RNAM
Avidity Biosciences Inc · Q1 2026 earnings
Q1 2026 earnings · · Investor relations
Briefing
Avidity Biosciences (RNAM) reported Q1 2026 revenue of ~$19.6M on RNA therapeutics development.
For the three months ended March 31, 2026, Avidity Biosciences reported approximately $19.6 million of revenue, primarily collaboration-based, while advancing DELIVER RNA programs in neuromuscular disease. Net loss reflects clinical trial and platform R&D spending on antibody-oligonucleotide conjugates.
- Revenue ~$19.6M from collaborations and milestones.
- DELIVER platform for targeted RNA therapeutics.
- Clinical programs in DM1 and other neuromuscular indications.
- R&D expense primary use of cash.
- Partnership funding supplements balance sheet.
Headline financials
Revenue & EPS history
Avidity Biosciences · Revenue · Quarterly
$19.6M
Revenue by segment
Avidity Biosciences · $2.82M total across 1 segment · Q3 2023
- Collaboration revenue$2.82M—100.0%
Forward guidance
Clinical-stage biotech; catalysts are trial readouts and partnership milestones rather than product revenue guidance.
Tailwinds
- Growing collaboration revenue versus early-stage peers.
- Differentiated AOC technology platform.
Headwinds
- Continued net losses until approvals.
- Clinical risk in neuromuscular trials.
- Competitive RNA and gene therapy landscape.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 8 quarterly earnings reports
+1.3%
Avg return
Earnings day
+4.7%
Avg return
5 days after
+8.2%
Avg return
30 days after
55%
12 / 22 earnings
Positive
+19.5%
Q4 2023
Best reaction
-12.5%
Q1 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | — | — | — | |
| Q4 2025 | — | — | — | |
| Q3 2025 | +1.3% | +1.4% | +2.5% | |
| Q2 2025 | -2.7% | -2.8% | +6.1% | |
| Q1 2025 | -0.6% | +1.3% | -2.0% | |
| Q4 2024 | +5.4% | +1.7% | +11.9% | |
| Q3 2024 | -1.1% | -1.1% | -18.9% | |
| Q2 2024 | +6.2% | +2.6% | -2.9% | |
| Q1 2024 | -0.4% | +11.0% | +2.2% | |
| Q4 2023 | +19.5% | +23.1% | +66.6% | |
| Q3 2023 | -6.0% | — | — | |
| Q2 2023 | +6.0% | — | — | |
| Q1 2023 | +4.0% | — | — | |
| Q4 2022 | +5.6% | — | — | |
| Q3 2022 | +5.7% | — | — | |
| Q2 2022 | +0.2% | — | — | |
| Q1 2022 | -9.4% | — | — | |
| Q4 2021 | +0.9% | — | — | |
| Q3 2021 | -0.5% | — | — | |
| Q2 2021 | -1.4% | — | — | |
| Q1 2021 | -12.5% | — | — | |
| Q4 2020 | +7.5% | — | — | |
| Q3 2020 | -1.0% | — | — | |
| Q2 2020 | +1.9% | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro